Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| 89R12486 MCF-F | ||
| By: Parker | S.B. No. 1827 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to investigational stem cell treatment. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Section 1003.051(1), Health and Safety Code, is | |
| amended to read as follows: | |
| (1) "Investigational stem cell treatment" means an | |
| adult stem cell treatment that: | |
| (A) is under investigation in a clinical trial | |
| and being administered to human participants in that trial; [ |
|
| (B) has not yet been approved for general use by | |
| the United States Food and Drug Administration; and | |
| (C) uses only adult stem cells that satisfy | |
| current good manufacturing practices adopted by the United States | |
| Food and Drug Administration. | |
| SECTION 2. Section 1003.054(c), Health and Safety Code, is | |
| amended to read as follows: | |
| (c) The executive commissioner by rule shall adopt a form | |
| for the informed consent under this section. The form must provide | |
| notice that: | |
| (1) the department administers this subchapter; and | |
| (2) the investigational stem cell treatment has not | |
| been approved for general use by the United States Food and Drug | |
| Administration. | |
| SECTION 3. Sections 1003.055(a) and (d), Health and Safety | |
| Code, are amended to read as follows: | |
| (a) Treatment provided under this subchapter must be: | |
| (1) administered directly by a physician certified | |
| under Subsection (c); | |
| (2) overseen by an institutional review board | |
| described by Subsection (d); and | |
| (3) provided [ |
|
| (A) at a hospital licensed under Chapter 241; | |
| (B) at an ambulatory surgical center licensed | |
| under Chapter 243; [ |
|
| (C) at a medical school, as defined by Section | |
| 61.501, Education Code; or | |
| (D) in an outpatient setting, as defined by | |
| Section 162.101, Occupations Code, listed by a physician registered | |
| under Section 162.104, Occupations Code, to provide level II | |
| anesthesia services in that setting. | |
| (d) An institutional review board that oversees | |
| investigational stem cell treatments administered under this | |
| subchapter must meet one of the following conditions: | |
| (1) be affiliated with a medical school, as defined by | |
| Section 61.501, Education Code; | |
| (2) be affiliated with a hospital licensed under | |
| Chapter 241 that has at least 150 beds; | |
| (3) be accredited by the Association for the | |
| Accreditation of Human Research Protection Programs; | |
| (4) be registered by the United States Department of | |
| Health and Human Services, Office for Human Research Protections, | |
| in accordance with 21 C.F.R. Part 56; [ |
|
| (5) be accredited by a national accreditation | |
| organization acceptable to the Texas Medical Board; or | |
| (6) be registered by the United States Department of | |
| Health and Human Services, Office for Human Research Protections, | |
| in accordance with 21 C.F.R. Part 56. | |
| SECTION 4. Section 1003.059(b), Health and Safety Code, is | |
| amended to read as follows: | |
| (b) Each institutional review board overseeing an | |
| investigational stem cell treatment under this subchapter shall | |
| submit to the Texas Medical Board an annual report on any serious | |
| adverse events related to the treatment and [ |
|
| Subsection (a). The report may not include any patient identifying | |
| information [ |
|
| SECTION 5. This Act takes effect September 1, 2025. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.